- Opportunistic screening AI achieves 92% AUC for CAC in head CTs (n=1,024).
- BTC at $75,815 with 1.7% gain, $1,517.2B cap (Apr 17, 2026).
- AI medtech valuations hit $50B; fear index drops to 21.
Opportunistic Screening AI Hits 92% AUC on 1,024 Patients
Opportunistic screening AI detects coronary artery calcium (CAC) in head CT scans. It achieves 92% area under the curve (AUC) accuracy. Cardiovascular Business reports this April 17, 2026. The model trained on 5,000+ paired head-chest CTs.
Biohackers pair it with Oura Ring HRV for vascular insights. No added radiation or costs.
CNNs Enable Head CT CAC Scoring
Convolutional neural networks (CNNs) analyze head CT voxels. They segment hearts and calculate Agatston scores. Paired scans with gated chest CTs trained the model. Radiologists validated results.
Cardiovascular Business used human data only. Peter Attia, MD, notes CAC predicts all-cause mortality better than cholesterol (Drive podcast, 2023).
ETH trades at $2,360, up 1.2% ($284.8B cap). Markets undervalue AI diagnostics.
CAC Predicts MI Risk in MESA Cohort
CAC scores boost myocardial infarction hazard ratio 2.5-fold per 100 units. The Multi-Ethnic Study of Atherosclerosis (MESA; 2008-2016, n=6,814) shows this. Early detection spurs Zone 2 training.
Rhonda Patrick, PhD, ties vascular stiffness to healthspan loss (FoundMyFitness, 2024). Hospitals integrate via PACS.
SOL jumps 4.2% to $88.65. AI health tokens rise.
AI Radiology Funding Reaches $200M
Tempus AI raised $200M VC (2024 filings). BlackRock medtech ETFs gain 15% YTD.
Bitcoin hits $75,815, up 1.7% ($1,517.2B cap), per CoinGecko April 17, 2026. Fear & Greed Index sits at 21 (extreme fear).
XRP rises 2.6% to $1.45 ($89.3B cap). Longevity VCs eye PathAI peers.
Biohacking Integrates Opportunistic Screening
Stack CAC with nicotinamide riboside (NR; 300-500mg daily, GRG trials preliminary; not FDA-approved for longevity). Track via annual scans.
Saunas (20min at 80°C) cut CVD hazard ratio to 0.77 (Laukkanen et al., JAMA Internal Medicine 2015; n=2,315 Finns). Andrew Huberman, PhD, details nitric oxide (Huberman Lab, 2023).
USDT stable at $1.00 ($185.8B supply). DeFi funds biohacking DAOs.
Transfer Learning Boosts 95% Accuracy
Transfer learning from chest CTs delivers 95% Dice score on aorta. AWS GPUs run inference.
DeepMind AI spots eye disease at 94% sensitivity (2020). NVIDIA GPUs power it; NVDA stock climbs.
BNB up 1.7% to $633 ($85.4B cap).
$50B AI Medtech Draws Longevity Capital
AI medtech hits $50B valuation (CB Insights 2026). Crypto volatility: WBT +1.8% to $55.30, ADA +3.8% to $0.26, DOGE +3.0% to $0.10.
Opportunistic screening scales globally. FDA clearance eyed Q3 2026. Biohackers demand AI CAC on head CTs. Pair with metformin (1g BID; TAME trial NCT02432287, ongoing Phase 3). Vascular data drives healthspan gains.
Frequently Asked Questions
What is opportunistic screening AI?
AI repurposes head CT scans for CAC scoring without new imaging. Cardiovascular Business reports 92% AUC on n=1,024 cohort, April 17, 2026.
How accurate is AI heart detection from head CTs?
Deep learning achieves 0.92 AUC via paired CT training. Radiologist-validated for clinical use.
Why integrate with longevity biohacking?
CAC tracks vascular aging; pair with Zone 2 and NAD+. Attia emphasizes early intervention.
What market trends link to this AI?
BTC $75,815 (+1.7%), fear index 21. AI medtech funding surges; SOL +4.2%.



